These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11985789)

  • 1. Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells.
    Akutsu Y; Nakayama T; Harada M; Kawano T; Motohashi S; Shimizu E; Ito T; Kamada N; Saito T; Matsubara H; Miyazawa Y; Ochiai T; Taniguchi M
    Jpn J Cancer Res; 2002 Apr; 93(4):397-403. PubMed ID: 11985789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Translational research in patients with lung cancer--clinical application of NKT cell immunotherapy].
    Motohashi S
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):550-3. PubMed ID: 17431340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
    Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
    Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.
    Fujii S; Shimizu K; Hemmi H; Fukui M; Bonito AJ; Chen G; Franck RW; Tsuji M; Steinman RM
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11252-7. PubMed ID: 16844772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.
    Toura I; Kawano T; Akutsu Y; Nakayama T; Ochiai T; Taniguchi M
    J Immunol; 1999 Sep; 163(5):2387-91. PubMed ID: 10452972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syntheses of biotinylated alpha-galactosylceramides and their effects on the immune system and CD1 molecules.
    Sakai T; Naidenko OV; Iijima H; Kronenberg M; Koezuka Y
    J Med Chem; 1999 May; 42(10):1836-41. PubMed ID: 10346936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.
    Smyth MJ; Wallace ME; Nutt SL; Yagita H; Godfrey DI; Hayakawa Y
    J Exp Med; 2005 Jun; 201(12):1973-85. PubMed ID: 15967825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
    Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
    J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.
    Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H
    Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
    Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide.
    Togashi Y; Chamoto K; Wakita D; Tsutsumi N; Iwakura Y; Matsubara N; Kitamura H; Nishimura T
    Cancer Sci; 2007 May; 98(5):721-5. PubMed ID: 17359285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.
    Nieda M; Nicol A; Koezuka Y; Kikuchi A; Lapteva N; Tanaka Y; Tokunaga K; Suzuki K; Kayagaki N; Yagita H; Hirai H; Juji T
    Blood; 2001 Apr; 97(7):2067-74. PubMed ID: 11264173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
    Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
    Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD1d-expressing dendritic cells but not thymic epithelial cells can mediate negative selection of NKT cells.
    Chun T; Page MJ; Gapin L; Matsuda JL; Xu H; Nguyen H; Kang HS; Stanic AK; Joyce S; Koltun WA; Chorney MJ; Kronenberg M; Wang CR
    J Exp Med; 2003 Apr; 197(7):907-18. PubMed ID: 12682110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells.
    Nakui M; Ohta A; Sekimoto M; Sato M; Iwakabe K; Yahata T; Kitamura H; Koda T; Kawano T; Makuuchi H; Taniguchi M; Nishimura T
    Clin Exp Metastasis; 2000; 18(2):147-53. PubMed ID: 11235990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver.
    Miyagi T; Takehara T; Tatsumi T; Kanto T; Suzuki T; Jinushi M; Sugimoto Y; Sasaki Y; Hori M; Hayashi N
    Int J Cancer; 2003 Aug; 106(1):81-9. PubMed ID: 12794761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
    Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
    J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand.
    Kawano T; Tanaka Y; Shimizu E; Kaneko Y; Kamata N; Sato H; Osada H; Sekiya S; Nakayama T; Taniguchi M
    Int Immunol; 1999 Jun; 11(6):881-7. PubMed ID: 10360961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
    Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
    J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.